Telavancin matches vancomycin for SSSIs but has more side effects

10/18/2011 | SkinAndAllergyNews.com

Telavancin and vancomycin had similar cure rates, 72% and 73%, respectively, for skin and skin structure infections in obese patients, though the serious adverse event rate was higher in the telavancin group (11% compared with 3%), according to an analysis of two late-stage trials.

View Full Article in:

SkinAndAllergyNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Deputy Director, Marketing
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Director of Operations - GBS
Mayo Clinic
MN
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC